- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01385319
Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study (ZEUS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The aim of this study is to conduct a multicenter, international, randomized trial to test whether the Endeavor stent is superior to BMS in terms of efficacy and safety in
- Patients with coronary artery disease lesions at low risk of in-stent restenosis;
- Patients at high risk for bleeding or carrying impossibility to comply with dual anti-platelet treatment at long-term.
- Patients at high thrombosis risk due to systemic disorders or planned non-cardiac surgery within 12 months
As the use of DES in these two patient/lesion subsets is debated due to lack of evidence, patients fulfilling at least one of these three medical conditions qualify for bare metal stent implantation and physicians may believe DES to be even contra-indicated in such cases. The current protocol has been developed on purpose to address the value of the Endeavor Sprint stent, which differs in many aspects from other FDA approved DES, including fast and complete degree of strut coverage after implantation and quick release of active drug after deployment (~15 days) which may help decreasing the need for prolonged dual antiplatelet treatment down to 1 month as it is currently recommended for bare metal stent implantation.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Szeged, Hungary
- Albert Szent-Györgyi Clinical Center, University of Szeged
-
-
-
-
-
Ferrara, Italy, 44100
- University Hospital of Ferrara
-
Naples, Italy, 80122
- Clinica Mediterranea
-
-
AR
-
Arezzo, AR, Italy, 52100
- Ospedale San Donato
-
-
BG
-
Bergamo, BG, Italy, 24128
- Ospedali Riuniti di Bergamo
-
Zingonia, BG, Italy, 24040
- Policlinico San Marco
-
-
CN
-
Savigliano, CN, Italy, 12038
- Ospedale di Savigliano
-
-
MI
-
Milano, MI, Italy, 20149
- Istituto Clinico Sant'Ambrogio
-
-
MO
-
Modena, MO, Italy, 41100
- Azienda Unita' Sanitaria Locale Di Modena - Ospedale Baggiovara
-
-
PR
-
Parma, PR, Italy, 43126
- Azienda Ospedaliero-Universitaria di Parma
-
-
PV
-
Pavia, PV, Italy, 27100
- Policlinico San Matteo
-
-
RA
-
Ravenna, RA, Italy, 48121
- Ospedale di Ravenna
-
-
TO
-
Torino, TO, Italy, 10154
- Ospedale San Giovanni Bosco
-
Torino, TO, Italy, 10128
- Azienda Ospedaliera Ordine Mauriziano di Torino, Ospedale Umberto I
-
-
-
-
-
Carnaxide, Portugal
- Hospital de Santa Cruz
-
-
-
-
-
Geneva, Switzerland
- University Hospital of Geneva
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
A) low restenosis risk based on angiographic findings defined as follows:
----patients will be considered at low restenosis risk if no planned stent lower than 3.0 mm is intended to be implanted in lesions expect left main or vein graft
B) high bleeding risk and/or presence of relative-absolute contraindication to dual anti-platelet treatment beyond 30 days defined as follows:
- Clinical indication to treatment with oral anticoagulant, including use of warfarin or dabigatran or other oral anticoagulant agents
- Recent (within previous 12 months) bleeding episode(s) which required medical attention
- Previous bleeding episode(s) which required hospitalization if the bleeding diathesis has not been completely resolved (i.e. surgical removal of the bleeding source)
- Age greater than 80
- Systemic conditions associated to increased bleeding risk (e.g. hematological disorders or any known coagulopathy determining bleeding diathesis, including history of or current thrombocytopenia defined as platelet count <100,000/mm3 (<100 x 109/L).
- Known Anemia defined as repeatedly documented hemoglobin lower than 10 gr/dl which is not due to an acute and documented blood loss
- Need for chronic treatment with steroids or NSAID
C) Patients at high thrombosis risk based on the presence of at least one of the following criteria:
- Allergy/intolerance to aspirin
- Allergy/intolerance to clopidogrel AND ticlopidine
- Planned surgery (other than skin) within 12 months of percutaneous coronary intervention (PCI).
- patient with cancers (other than skin) and life expectancy >1 year
Patients with systemic conditions associated with thrombosis diathesis (e.g., hematologic disorders and any known systemic conditions determining a pro-thrombotic state including immunological disorders)
-
Exclusion Criteria:
Any of the following:
- Women who are pregnant. Women of childbearing potential must have a negative pregnancy test (urine or serum HCG) within 7 days prior to randomization; as close to randomization as possible, within 24 hours preferred.
- Subjects who are unable to give informed consent and assurance for complete contact through 12 months.
- PCI with stenting in the previous 6 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: bare metal stent
|
After BMS implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient as follows: Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients. Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days. Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month. |
Experimental: Endeavor sprint stent
|
After ZES implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient (i.e. identical to criteria set out for BMS patients) as follows: Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients. Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days. Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MACE
Time Frame: 12 months
|
Major adverse cardiovascular events including death for any cause, non-fatal myocardial infarction or target vessel revascularisation
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Death
Time Frame: 12 months
|
12 months
|
|
myocardial infarction
Time Frame: 12 months
|
12 months
|
|
stent thrombosis
Time Frame: 12 months
|
12 months
|
|
TVR
Time Frame: 12 months
|
target vessel revascularisation
|
12 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Ariotti S, Adamo M, Costa F, Patialiakas A, Briguori C, Thury A, Colangelo S, Campo G, Tebaldi M, Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo R, Meliga E, Testa L, Gabriel HM, Ferlini M, Vranckx P, Valgimigli M; ZEUS Investigators. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial. JACC Cardiovasc Interv. 2016 Mar 14;9(5):426-36. doi: 10.1016/j.jcin.2015.11.015.
- Valgimigli M, Patialiakas A, Thury A, McFadden E, Colangelo S, Campo G, Tebaldi M, Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo R, Meliga E, Testa L, Gabriel HM, Airoldi F, Ferlini M, Liistro F, Dellavalle A, Vranckx P, Briguori C; ZEUS Investigators. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol. 2015 Mar 3;65(8):805-815. doi: 10.1016/j.jacc.2014.11.053.
- Valgimigli M, Patialiakas A, Thury A, Colangelo S, Campo G, Tebaldi M, Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo R, Meliga E, Testa L, Gabriel HM, Airoldi F, Ferlini M, Liistro F, Dellavalle A, Vranckx P, Briguori C. Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in uncertain DES candidates study. Am Heart J. 2013 Nov;166(5):831-8. doi: 10.1016/j.ahj.2013.07.033. Epub 2013 Sep 26.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZEUS-10-II
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Bare metal stent implantation
-
Fabrizio D'AscenzoUniversity of Zurich; University of Bologna; University of Roma La Sapienza; Azienda... and other collaboratorsUnknownCoronary Artery Disease | Heart Transplant Failure and RejectionItaly
-
A.O. Ospedale Papa Giovanni XXIIIMedtronic; Case Western Reserve UniversityCompletedAcute Myocardial InfarctionItaly
-
University Hospital, SaarlandCompletedCoronary Artery DiseaseGermany
-
University of SaskatchewanUnknown
-
Biotronik AGCompletedDe Novo and Re-stenosed Coronary Artery LesionsSwitzerland, Netherlands, Israel, Spain, Latvia, Germany, Austria, Belgium, France, Ireland
-
Catholic University of the Sacred HeartCompletedSaphenous Vein Graft Disease
-
Chinese Society of Interventional RadiologyCompletedVertebral Artery Origin StenosisChina
-
Boston Scientific CorporationCompletedSymptomatic Ischemic Saphenous Vein Graft DiseaseUnited States, Canada
-
European HospitalCompletedChronic Kidney Disease | Multivessel Coronary Artery DiseaseItaly
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceCompletedDysfunction of the Prosthetic Conduct | Lesions of the Right Ventricular Outflow TractFrance